0001209191-23-006789.txt : 20230203 0001209191-23-006789.hdr.sgml : 20230203 20230203160923 ACCESSION NUMBER: 0001209191-23-006789 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230201 FILED AS OF DATE: 20230203 DATE AS OF CHANGE: 20230203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Laponis Adam CENTRAL INDEX KEY: 0001827198 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39616 FILM NUMBER: 23585856 MAIL ADDRESS: STREET 1: C/O EARGO, INC. STREET 2: 2665 NORTH FIRST STREET, SUITE 300 CITY: SAN JOSE STATE: CA ZIP: 95134 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eargo, Inc. CENTRAL INDEX KEY: 0001719395 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 273879804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2665 NORTH FIRST STREET STREET 2: SUITE 300 CITY: SAN JOSE STATE: CA ZIP: 95134 BUSINESS PHONE: 650-351-7700 MAIL ADDRESS: STREET 1: 2665 NORTH FIRST STREET STREET 2: SUITE 300 CITY: SAN JOSE STATE: CA ZIP: 95134 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-01 0 0001719395 Eargo, Inc. EAR 0001827198 Laponis Adam C/O EARGO, INC. 2665 NORTH FIRST STREET, SUITE 300 SAN JOSE CA 95134 0 1 0 0 Chief Financial Officer Stock Option (Right to Buy) 11.58 2023-02-01 4 A 0 82500 0.00 A 2033-01-31 Common Stock 82500 82500 D Stock Option (Right to Buy) 11.58 2023-02-01 4 A 0 82500 0.00 A 2033-01-31 Common Stock 82500 82500 D The Stock Option vests and becomes exercisable as to 20% of the shares subject to the stock option on February 15, 2024 (the "Vesting Start Date"), with the remainder vesting in 16 equal quarterly installments thereafter until all of the shares subject to the stock option have vested and become exercisable on the fourth anniversary of the Vesting Start Date, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through each such date. The Stock Option vests and becomes exercisable in full upon attainment of a 360-day VWAP (volume-weighted average price) of $20.00 for the Issuer's Common Stock on or prior to February 15, 2028, so long as the Reporting Person remains an employee, consultant, director or officer of the Issuer through such date. /s/ Christy La Pierre, Attorney-in-Fact for Adam Laponis 2023-02-03